Effects of daily glucose fluctuations on the healing response to everolimus-eluting stent implantation as assessed using continuous glucose monitoring and optical coherence tomography

Masaru Kuroda, Toshiro Shinke, Hiromasa Otake, Daisuke Sugiyama, Tomofumi Takaya, Hachidai Takahashi, Daisuke Terashita, Kenzo Uzu, Natsuko Tahara, Daiji Kashiwagi, Koji Kuroda, Yuto Shinkura, Yoshinori Nagasawa, Kazuhiko Sakaguchi, Yushi Hirota, Wataru Ogawa, Ken ichi Hirata

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Several studies have revealed that glucose fluctuations provoke oxidative stress that leads to endothelial cell dysfunction, progression of coronary atherosclerosis, and plaque vulnerability. However, little is known regarding their effect on neointimal growth after stenting in patients with coronary artery disease (CAD). We aimed to investigate the effects of glucose fluctuations on neointimal growth after everolimus-eluting stent (EES) implantation. Methods: This study examined 50 patients who underwent a 9-month follow-up using optical coherence tomography (OCT) after EES implantation. Glucose fluctuation was expressed as the mean amplitude of glycemic excursion (MAGE), and was determined via continuous glucose monitoring before stenting. At the OCT follow-up, we evaluated the percentage of uncovered struts and three-dimensional uniformity of neointimal distribution by calculating the mean neointimal thickness (NIT) within 360 equally-spaced radial sectors for every 1-mm cross-sectional OCT analysis, and assessed the incidence of major adverse cardiovascular events (MACE). Results: We evaluated 60 lesions in 50 patients. Linear mixed effect models were used to explore the influence of different variables on variability in NIT and the percentage of uncovered struts and to adjust for covariates. Univariate analysis showed that MAGE was most strongly correlated with the previously mentioned OCT measurements (coefficient β±standard error=0.267±0.073 and 0.016±0.003, t=3.668 and 6.092, both P<0.001, respectively). In multivariate analysis, MAGE had the strongest effect on variability in NIT (coefficient β±standard error=0.239±0.093, P=0.014) and the percentage of uncovered struts (coefficient β±standard error=0.019±0.004, P<0.001). Five lesions in four patients required target lesion revascularization (10.0%) at a mean duration of 9months after EES implantation. Compared to non-MACE cases, cases of MACE exhibited a significantly higher MAGE (99vs.68; P=0.004), maximum NIT (580vs. 330μm; P=0.002), and variability in NIT (100vs.65; P=0.007), although there was no significant difference in these groups' HbA1c levels. Conclusions: Glucose fluctuation may affect vessel healing after EES implantation in patients with CAD who are receiving lipid-lowering therapy. Therefore, glucose fluctuations may be an important target for secondary prevention after coronary stenting, which is independent of dyslipidemia control.

Original languageEnglish
Article number79
JournalCardiovascular Diabetology
Volume15
Issue number1
DOIs
Publication statusPublished - 2016 May 21

Fingerprint

Optical Coherence Tomography
Stents
Glucose
Coronary Artery Disease
Dyslipidemias
Growth
Secondary Prevention
Everolimus
Oxidative Stress
Multivariate Analysis
Endothelial Cells
Lipids
Incidence

Keywords

  • Continuous glucose monitoring
  • Glucose fluctuation
  • Mean amplitude of glycemic excursion
  • Optical coherence tomography

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of daily glucose fluctuations on the healing response to everolimus-eluting stent implantation as assessed using continuous glucose monitoring and optical coherence tomography. / Kuroda, Masaru; Shinke, Toshiro; Otake, Hiromasa; Sugiyama, Daisuke; Takaya, Tomofumi; Takahashi, Hachidai; Terashita, Daisuke; Uzu, Kenzo; Tahara, Natsuko; Kashiwagi, Daiji; Kuroda, Koji; Shinkura, Yuto; Nagasawa, Yoshinori; Sakaguchi, Kazuhiko; Hirota, Yushi; Ogawa, Wataru; Hirata, Ken ichi.

In: Cardiovascular Diabetology, Vol. 15, No. 1, 79, 21.05.2016.

Research output: Contribution to journalArticle

Kuroda, M, Shinke, T, Otake, H, Sugiyama, D, Takaya, T, Takahashi, H, Terashita, D, Uzu, K, Tahara, N, Kashiwagi, D, Kuroda, K, Shinkura, Y, Nagasawa, Y, Sakaguchi, K, Hirota, Y, Ogawa, W & Hirata, KI 2016, 'Effects of daily glucose fluctuations on the healing response to everolimus-eluting stent implantation as assessed using continuous glucose monitoring and optical coherence tomography', Cardiovascular Diabetology, vol. 15, no. 1, 79. https://doi.org/10.1186/s12933-016-0395-4
Kuroda, Masaru ; Shinke, Toshiro ; Otake, Hiromasa ; Sugiyama, Daisuke ; Takaya, Tomofumi ; Takahashi, Hachidai ; Terashita, Daisuke ; Uzu, Kenzo ; Tahara, Natsuko ; Kashiwagi, Daiji ; Kuroda, Koji ; Shinkura, Yuto ; Nagasawa, Yoshinori ; Sakaguchi, Kazuhiko ; Hirota, Yushi ; Ogawa, Wataru ; Hirata, Ken ichi. / Effects of daily glucose fluctuations on the healing response to everolimus-eluting stent implantation as assessed using continuous glucose monitoring and optical coherence tomography. In: Cardiovascular Diabetology. 2016 ; Vol. 15, No. 1.
@article{6ba4ddb0d8894141b57aec766edf4c28,
title = "Effects of daily glucose fluctuations on the healing response to everolimus-eluting stent implantation as assessed using continuous glucose monitoring and optical coherence tomography",
abstract = "Background: Several studies have revealed that glucose fluctuations provoke oxidative stress that leads to endothelial cell dysfunction, progression of coronary atherosclerosis, and plaque vulnerability. However, little is known regarding their effect on neointimal growth after stenting in patients with coronary artery disease (CAD). We aimed to investigate the effects of glucose fluctuations on neointimal growth after everolimus-eluting stent (EES) implantation. Methods: This study examined 50 patients who underwent a 9-month follow-up using optical coherence tomography (OCT) after EES implantation. Glucose fluctuation was expressed as the mean amplitude of glycemic excursion (MAGE), and was determined via continuous glucose monitoring before stenting. At the OCT follow-up, we evaluated the percentage of uncovered struts and three-dimensional uniformity of neointimal distribution by calculating the mean neointimal thickness (NIT) within 360 equally-spaced radial sectors for every 1-mm cross-sectional OCT analysis, and assessed the incidence of major adverse cardiovascular events (MACE). Results: We evaluated 60 lesions in 50 patients. Linear mixed effect models were used to explore the influence of different variables on variability in NIT and the percentage of uncovered struts and to adjust for covariates. Univariate analysis showed that MAGE was most strongly correlated with the previously mentioned OCT measurements (coefficient β±standard error=0.267±0.073 and 0.016±0.003, t=3.668 and 6.092, both P<0.001, respectively). In multivariate analysis, MAGE had the strongest effect on variability in NIT (coefficient β±standard error=0.239±0.093, P=0.014) and the percentage of uncovered struts (coefficient β±standard error=0.019±0.004, P<0.001). Five lesions in four patients required target lesion revascularization (10.0{\%}) at a mean duration of 9months after EES implantation. Compared to non-MACE cases, cases of MACE exhibited a significantly higher MAGE (99vs.68; P=0.004), maximum NIT (580vs. 330μm; P=0.002), and variability in NIT (100vs.65; P=0.007), although there was no significant difference in these groups' HbA1c levels. Conclusions: Glucose fluctuation may affect vessel healing after EES implantation in patients with CAD who are receiving lipid-lowering therapy. Therefore, glucose fluctuations may be an important target for secondary prevention after coronary stenting, which is independent of dyslipidemia control.",
keywords = "Continuous glucose monitoring, Glucose fluctuation, Mean amplitude of glycemic excursion, Optical coherence tomography",
author = "Masaru Kuroda and Toshiro Shinke and Hiromasa Otake and Daisuke Sugiyama and Tomofumi Takaya and Hachidai Takahashi and Daisuke Terashita and Kenzo Uzu and Natsuko Tahara and Daiji Kashiwagi and Koji Kuroda and Yuto Shinkura and Yoshinori Nagasawa and Kazuhiko Sakaguchi and Yushi Hirota and Wataru Ogawa and Hirata, {Ken ichi}",
year = "2016",
month = "5",
day = "21",
doi = "10.1186/s12933-016-0395-4",
language = "English",
volume = "15",
journal = "Cardiovascular Diabetology",
issn = "1475-2840",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Effects of daily glucose fluctuations on the healing response to everolimus-eluting stent implantation as assessed using continuous glucose monitoring and optical coherence tomography

AU - Kuroda, Masaru

AU - Shinke, Toshiro

AU - Otake, Hiromasa

AU - Sugiyama, Daisuke

AU - Takaya, Tomofumi

AU - Takahashi, Hachidai

AU - Terashita, Daisuke

AU - Uzu, Kenzo

AU - Tahara, Natsuko

AU - Kashiwagi, Daiji

AU - Kuroda, Koji

AU - Shinkura, Yuto

AU - Nagasawa, Yoshinori

AU - Sakaguchi, Kazuhiko

AU - Hirota, Yushi

AU - Ogawa, Wataru

AU - Hirata, Ken ichi

PY - 2016/5/21

Y1 - 2016/5/21

N2 - Background: Several studies have revealed that glucose fluctuations provoke oxidative stress that leads to endothelial cell dysfunction, progression of coronary atherosclerosis, and plaque vulnerability. However, little is known regarding their effect on neointimal growth after stenting in patients with coronary artery disease (CAD). We aimed to investigate the effects of glucose fluctuations on neointimal growth after everolimus-eluting stent (EES) implantation. Methods: This study examined 50 patients who underwent a 9-month follow-up using optical coherence tomography (OCT) after EES implantation. Glucose fluctuation was expressed as the mean amplitude of glycemic excursion (MAGE), and was determined via continuous glucose monitoring before stenting. At the OCT follow-up, we evaluated the percentage of uncovered struts and three-dimensional uniformity of neointimal distribution by calculating the mean neointimal thickness (NIT) within 360 equally-spaced radial sectors for every 1-mm cross-sectional OCT analysis, and assessed the incidence of major adverse cardiovascular events (MACE). Results: We evaluated 60 lesions in 50 patients. Linear mixed effect models were used to explore the influence of different variables on variability in NIT and the percentage of uncovered struts and to adjust for covariates. Univariate analysis showed that MAGE was most strongly correlated with the previously mentioned OCT measurements (coefficient β±standard error=0.267±0.073 and 0.016±0.003, t=3.668 and 6.092, both P<0.001, respectively). In multivariate analysis, MAGE had the strongest effect on variability in NIT (coefficient β±standard error=0.239±0.093, P=0.014) and the percentage of uncovered struts (coefficient β±standard error=0.019±0.004, P<0.001). Five lesions in four patients required target lesion revascularization (10.0%) at a mean duration of 9months after EES implantation. Compared to non-MACE cases, cases of MACE exhibited a significantly higher MAGE (99vs.68; P=0.004), maximum NIT (580vs. 330μm; P=0.002), and variability in NIT (100vs.65; P=0.007), although there was no significant difference in these groups' HbA1c levels. Conclusions: Glucose fluctuation may affect vessel healing after EES implantation in patients with CAD who are receiving lipid-lowering therapy. Therefore, glucose fluctuations may be an important target for secondary prevention after coronary stenting, which is independent of dyslipidemia control.

AB - Background: Several studies have revealed that glucose fluctuations provoke oxidative stress that leads to endothelial cell dysfunction, progression of coronary atherosclerosis, and plaque vulnerability. However, little is known regarding their effect on neointimal growth after stenting in patients with coronary artery disease (CAD). We aimed to investigate the effects of glucose fluctuations on neointimal growth after everolimus-eluting stent (EES) implantation. Methods: This study examined 50 patients who underwent a 9-month follow-up using optical coherence tomography (OCT) after EES implantation. Glucose fluctuation was expressed as the mean amplitude of glycemic excursion (MAGE), and was determined via continuous glucose monitoring before stenting. At the OCT follow-up, we evaluated the percentage of uncovered struts and three-dimensional uniformity of neointimal distribution by calculating the mean neointimal thickness (NIT) within 360 equally-spaced radial sectors for every 1-mm cross-sectional OCT analysis, and assessed the incidence of major adverse cardiovascular events (MACE). Results: We evaluated 60 lesions in 50 patients. Linear mixed effect models were used to explore the influence of different variables on variability in NIT and the percentage of uncovered struts and to adjust for covariates. Univariate analysis showed that MAGE was most strongly correlated with the previously mentioned OCT measurements (coefficient β±standard error=0.267±0.073 and 0.016±0.003, t=3.668 and 6.092, both P<0.001, respectively). In multivariate analysis, MAGE had the strongest effect on variability in NIT (coefficient β±standard error=0.239±0.093, P=0.014) and the percentage of uncovered struts (coefficient β±standard error=0.019±0.004, P<0.001). Five lesions in four patients required target lesion revascularization (10.0%) at a mean duration of 9months after EES implantation. Compared to non-MACE cases, cases of MACE exhibited a significantly higher MAGE (99vs.68; P=0.004), maximum NIT (580vs. 330μm; P=0.002), and variability in NIT (100vs.65; P=0.007), although there was no significant difference in these groups' HbA1c levels. Conclusions: Glucose fluctuation may affect vessel healing after EES implantation in patients with CAD who are receiving lipid-lowering therapy. Therefore, glucose fluctuations may be an important target for secondary prevention after coronary stenting, which is independent of dyslipidemia control.

KW - Continuous glucose monitoring

KW - Glucose fluctuation

KW - Mean amplitude of glycemic excursion

KW - Optical coherence tomography

UR - http://www.scopus.com/inward/record.url?scp=84969580024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969580024&partnerID=8YFLogxK

U2 - 10.1186/s12933-016-0395-4

DO - 10.1186/s12933-016-0395-4

M3 - Article

C2 - 27208906

AN - SCOPUS:84969580024

VL - 15

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

SN - 1475-2840

IS - 1

M1 - 79

ER -